12月23日，亨迪药业跌2.35%，成交额8800.87万元。两融数据显示，当日亨迪药业获融资买入额755.87 万元，融资偿还623.12万元，融资净买入132.75万元。截至12月23日，亨迪药业融资融券余额合计1.24 亿元。 融资方面，亨迪药业当日融资买入755.87万元。当前融资余额1.24亿元，占流通市值的2.39%，融资余 额低于近一年50%分位水平，处于较低位。 融券方面，亨迪药业12月23日融券偿还900.00股，融券卖出900.00股，按当日收盘价计算，卖出金额 1.12万元；融券余量2.23万股，融券余额27.74万元，超过近一年90%分位水平，处于高位。 资料显示，湖北亨迪药业股份有限公司位于湖北省荆门市掇刀区杨湾路122号，成立日期1995年12月29 日，上市日期2021年12月22日，公司主营业务涉及化学原料药及制剂产品的研发、生产和销售。主营业 务收入构成为：非甾体抗炎类68.06%，心血管类16.08%，其他8.86%，抗肿瘤类6.99%。 责任编辑：小浪快报 分红方面，亨迪药业A股上市后累计派现3.78亿元。近三年，累计派现3.06亿元。 机构持仓方面，截止2025年9月3 ...

证券日报网讯12月23日，亨迪药业（301211）在互动平台回答投资者提问时表示，截至2025年12月19 日，公司股东户数为21381户。 ...

证券日报网讯12月15日，亨迪药业（301211）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东户数为22076户。 ...

亨迪药业12月15日披露，截至12月10日公司股东户数为22076户，较上期（11月30日）减少2079户，环 比降幅为8.61%。 证券时报·数据宝统计，截至发稿，亨迪药业最新股价为12.74元，下跌0.39%，本期筹码集中以来股价 累计下跌16.13%。具体到各交易日，1次上涨，10次下跌。 公司发布的三季报数据显示，前三季公司共实现营业收入3.19亿元，同比下降4.52%，实现净利润 2093.34万元，同比下降71.96%，基本每股收益为0.0500元，加权平均净资产收益率0.92%。（数据宝） （文章来源：证券时报网） ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | | | | | 2025-12-02 | 301211 | 享適药业 | 12.37 | 16.28 | | 201.38 方正证券股份有限 | 国泰海通证券股份 | | | | | | | | 公司上海杨高南路 | 有限公司上海临港 | | | | | | | | 证券营业部 | 新片区分公司 | 12月2日，亨迪药业大宗交易成交16.28万股，成交额201.38万元，占当日总成交额的1.16%，成交价 12.37元，较市场收盘价14.75元折价16.14%。 ...

Group 1 - The core point of the article is that Hendi Pharmaceutical (301211) reported a total of 24,155 shareholders as of November 28, 2025 [1]

Group 1 - The flu-related concept has become active again, with Haiwang Bio hitting the daily limit up [2] - Yue Wannianqing has increased by over 12% [2] - Other companies such as Guangji Pharmaceutical, Hendi Pharmaceutical, Te Yi Pharmaceutical, Jinshi Yiyao, and Xinhua Pharmaceutical have also seen gains [2]

Group 1 - The hepatitis concept sector declined by 0.31%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the hepatitis sector that saw significant outflows include Zhongsheng Pharmaceutical with a net outflow of 684 million yuan, followed by Te Yi Pharmaceutical and Pian Zai Huang with net outflows of 112 million yuan and 81 million yuan respectively [2][3] - Conversely, stocks that experienced net inflows include Baihua Pharmaceutical, Huadong Medicine, and Kangzhi Pharmaceutical, with inflows of 97.75 million yuan, 43.11 million yuan, and 21.20 million yuan respectively [6] Group 2 - The top gainers in the hepatitis sector included Baihua Pharmaceutical, which rose by 10.01%, followed by Chengda Pharmaceutical and Kangzhi Pharmaceutical with increases of 4.79% and 3.00% respectively [1][6] - The overall market sentiment for the hepatitis sector appears negative, as evidenced by the significant net outflows and the number of stocks declining in value [2][3] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78%, indicating active trading despite the price drop [2][3]

Core Viewpoint - The A-share market experienced a significant rally on November 25, with the ChiNext Index rising nearly 2%, driven by a surge in flu-related stocks due to an increase in flu activity across the country [1] Group 1: Market Performance - The ChiNext Index saw a nearly 2% increase on November 25, indicating strong market performance [1] - Flu-related stocks, such as Jindike and Xinhua Pharmaceutical, reached their daily limit up, reflecting heightened investor interest [1] Group 2: Flu Activity and Sales Data - National flu activity has rapidly increased in November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Sales of Oseltamivir surged by 237% over the past week, while sales of Maviral (Sofosbuvir) increased by 180% [1] - Data from Meituan indicates that special flu medications in Beijing have seen a month-on-month growth exceeding 130%, with Maviral growing over 110% and Oseltamivir granules increasing by over 85% [1] Group 3: Investment Opportunities - According to Everbright Securities, the rising flu epidemic is likely to increase public and market attention, leading to a growth in demand for flu prevention and treatment products [1] - Investment opportunities are suggested in flu vaccines, virus testing, cold medications, and special antiviral drugs, as well as blood products as a response to complex epidemic situations [1]

Core Viewpoint - The A-share market has seen significant movements in flu-related stocks, with several companies reaching their daily limit up due to increased demand amid a rising flu activity across the country [1] Group 1: Stock Performance - Companies such as Peking University Pharmaceutical (000788), Guangji Pharmaceutical (000952), and Hainan Haiyao (000566) experienced sharp increases, hitting the daily limit up [1] - Other stocks like Jindike and Te Yi Pharmaceutical (002728) also reached their daily limit up, with additional stocks such as Yipin Hong (300723) and Hendi Pharmaceutical (301211) following suit [1] Group 2: Market Context - The flu activity in the country is currently on a rapid rise, with reports indicating that Beijing has entered a high incidence period for respiratory infectious diseases [1] - Recent data shows a dramatic increase in sales of antiviral medications, with Oseltamivir sales surging by 237% over the past week, while the sales of Favipiravir (Mabalaosavir) increased by 180% [1]